Abstract:9049 Background: mTOR is a validated target in cancer treatment. mTOR mutations are estimated to be 2.46% of all cancers and 5.76% of cutaneous melanoma. However, mTOR mutations in other types of melanoma have not been reported. Methods: This study involved tumor samples from 412 Chinese melanoma patients, including 210 acral melanomas, 105 mucosal melanomas, 30 melanomas on skin with chronic sun-induced damage and 58 melanomas on skin without chronic sun-induced damage. Tissue samples were analyzed for mutations in all exons of mTOR gene in genomic DNA by Sanger sequencing. Mutation status was confirmed using Agilent’s sureselect target enrichment system. HEK293T cells stably expressing mutant mTOR were constructed by TALEN (Transcription Activator-like Effector Nucleases). Function of mTOR mutants in these cells and in vitro sensitivity of mTOR gain-of-function mutations to PI3K-AKT-mTOR pathway inhibitors were analyzed. Results: The overall incidence of somatic mutations within the mTOR gene was 10.4% (43/412). Increased mTOR mutations were relatively more frequent in acral (11.0%) and mucosal (14.4%) melanomas than in CSD (6.7%) and Non-CSD (3.4%) melanomas. Of the 43 cases with mTOR mutations, 41 different mutations were detected, affecting 25 different exons. Point mutations resulting in single amino acid substitutions (totaling 40 mutations detected in 43 patients) were the most common type of mTOR mutation. The median survival time for melanoma patients with mTOR mutation was significantly shorter than that for patients without mTOR mutation (P = 0.028). Transient expression of several mTOR mutants in HEK293 cells strongly activated the mTOR/p70S6K pathway. In HEK293 cells with stable expression of H1968Yor P2213S mTOR mutants, LY294002 and AZD5363 showed higher potency than Temsirolimus or BYL719 in inhibiting the mTOR/p70S6K pathway. Conclusions: These data demonstrate that mTOR mutations are more frequent in Chinese melanoma patients than in Caucasian melanoma patients. mTOR mutations is a worse prognostic factor in Chinese melanoma patients. Clinical trials with PI3K-AKT-mTOR pathway inhibitors may be beneficial for melanoma patients with mTOR mutations.

Supplementary Table S6 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure S1 from Analysis of <i>mtor</i> Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure S2 from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to Pi3k-Akt-Mtor Pathway Inhibitors

Analysis of Mtor Mutations in Chinese Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.

Figure Legends for Supplementary Figures from Analysis of Mtor Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Association of the Activation of the Mtor Pathway with Prognosis in Chinese Melanoma Patients.

PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.

Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics

Supplementary Figure 3 from Large-scale Analysis of <i>pdgfra</i> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Table 2 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Figure 3 from Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Supplementary Figure 2 from Large-scale Analysis of <i>pdgfra</i> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib

Mtor Pathway Activation in Kit-Mutated Melanoma with Acquired Imatinib Resistance.

A Subset of Metastatic Pancreatic Ductal Adenocarcinomas Depends Quantitatively on Oncogenic Kras/Mek/Erk-Induced Hyperactive Mtor Signalling

TABLE 3 from Phase I Study of Mtorc1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with <i>mtor/akt/pi3k</i> Pathway Alterations and Advanced Solid Malignancies

Supplementary Table 3 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

P1.03-33 Mutational Spectrum and Prognosis of Non-Small-Cell Lung Cancer Harboring MTOR Mutations in Chinese Population

Supplementary Table from AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway–Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B

Supplementary Table S6 from Analysis of &lt;i&gt;mtor&lt;/i&gt; Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors

Supplementary Figure S1 from Analysis of &lt;i&gt;mtor&lt;/i&gt; Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors